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Abstract
Background: Cancer associated with smoking and drinking remains a serious health problem worldwide. The survival of
patients is very poor due to the lack of effective early biomarkers. FOXM1 overexpression is linked to the majority of human
cancers but its mechanism remains unclear in head and neck squamous cell carcinoma (HNSCC).
Methodology/Principal Findings: FOXM1 mRNA and protein expressions were investigated in four independent cohorts
(total 75 patients) consisting of normal, premalignant and HNSCC tissues and cells using quantitative PCR (qPCR), expression
microarray, immunohistochemistry and immunocytochemistry. Effect of putative oral carcinogens on FOXM1 transcriptional
activity was dose-dependently assayed and confirmed using a FOXM1-specific luciferase reporter system, qPCR,
immunoblotting and short-hairpin RNA interference. Genome-wide single nucleotide polymorphism (SNP) array was used
to ‘trace’ the genomic instability signature pattern in 8 clonal lines of FOXM1-induced malignant human oral keratinocytes.
Furthermore, acute FOXM1 upregulation in primary oral keratinocytes directly induced genomic instability. We have shown
for the first time that overexpression of FOXM1 precedes HNSCC malignancy. Screening putative carcinogens in human oral
keratinocytes surprisingly showed that nicotine, which is not perceived to be a human carcinogen, directly induced FOXM1
mRNA, protein stabilisation and transcriptional activity at concentrations relevant to tobacco chewers. Importantly, nicotine
also augmented FOXM1-induced transformation of human oral keratinocytes. A centrosomal protein CEP55 and a DNA
helicase/putative stem cell marker HELLS, both located within a consensus loci (10q23), were found to be novel targets of
FOXM1 and their expression correlated tightly with HNSCC progression.
Conclusions/Significance: This study cautions the potential co-carcinogenic effect of nicotine in tobacco replacement
therapies. We hypothesise that aberrant upregulation of FOXM1 may be inducing genomic instability through a program of
malignant transformation involving the activation of CEP55 and HELLS which may facilitate aberrant mitosis and epigenetic
modifications. Our finding that FOXM1 is upregulated early during oral cancer progression renders FOXM1 an attractive
diagnostic biomarker for early cancer detection and its candidate mechanistic targets, CEP55 and HELLS, as indicators of
malignant conversion and progression.
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Introduction
The forkhead box (FOX) protein family of transcription factors
exhibit a myriad of biological functions such as regulation of cell
cycle, proliferation, apoptosis, differentiation and longevity during
embryonic development and adult tissue homeostasis [reviewed in
1]. The FOXM1 transcription factor (previously known as: HFH-
11, INS-1, WIN, MPP2/MPHOSPH2 or Trident/FKHL16) has
been shown to play important roles in cell cycle progression and
mitosis [reviewed in 2]. FOXM1-null mouse embryos were
neonatally lethal as a result of the development of polyploid
cardiomyocytes and hepatocytes, highlighting the role of FOXM1
in mitotic division [3]. More recently a study using transgenic/
knockout mouse embryonic fibroblasts and human osteosarcoma
cells (U2OS) has shown that FOXM1 regulates expression of a
large array of G2/M-specific genes such as PLK1, NEK2 and
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4849CENP-F, and plays an important role in the maintenance of
chromosomal segregation and genomic stability [4].
We originally established a link between FOXM1 and
tumourigenesis when we demonstrated that FOXM1 was a
downstream target of Gli1 in basal cell carcinoma (BCC) and
showed that of the three known alternatively spliced isoforms
(FOXM1A, B and C), FOXM1B isoform was overexpressed in
BCCs [5]. Both transcriptional activators FOXM1B and
FOXM1C are upregulated in the majority of solid human cancers
[reviewed in 2,6].
Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer worldwide. The average five-year survival of
patients is very poor (,50%) and it has not improved in the last 50
years [reviewed in 7]. This is mainly due to the lack of effective
diagnostic and prognostic methods which can guide appropriate
treatment strategy at early stages. Treatment often requires
extensive maxillofacial surgery which imposes significant morbid-
ity requiring long term multidisciplinary care hence further
increasing financial pressures on public health services. Therefore,
one of the keys to successful treatment and cure is early detection
of tumour formation.
Whilst the FOXM1 gene is now widely accepted to be a
commonly upregulated oncogene in majority of human solid
cancers, its role and mechanism in cancer initiation and
progression remain unclear. Herein, we present that FOXM1 is
significantly upregulated in human premalignant and HNSCC
tissues and cultured cells. Due to the fact that HNSCC has a
strong risk factor association, we questioned the role of FOXM1 in
response to common oral carcinogens often present in the oral
mucosa. A preliminary screen of oral carcinogens surprisingly
showed that nicotine activated endogenous activity of FOXM1 in
human oral keratinocytes. As tobacco is one of the main etiological
factors for HNSCC and nicotine is one of the major alkaloids
found in tobacco, we studied the role of nicotine in carcinogenesis
through activation of FOXM1 (isoform B). We now show that
FOXM1B is upregulated early in HNSCC development and acts
in concert with nicotine to promote anchorage-independent
growth. High-density SNP analysis of anchorage-independent
transformed cell clones revealed 2 candidate downstream effectors
of FOXM1B action, which are overexpressed in malignant SCC
lines. The present study investigated the effect of nicotine and the
mechanism of FOXM1 in HNSCC using a combination of
molecular, cellular, tissue, microarray and bioinformatics ap-
proaches.
Results
Upregulation of FOXM1 precedes HNSCC malignancy
To investigate the expression levels of endogenous FOXM1 we
initially used semi-quantitative RT-PCR on a tissue panel of
normal human oral mucosa, oral dysplasia, HNSCC tissues and
various oral keratinocyte lines (Fig 1A). Total FOXM1 mRNA
expression was low in normal mucosa whilst a trend of progressive
increase in expression from premalignant to malignant tissues was
detected. In support, a well characterised premalignant buccal
keratinocyte line SVpgC2a [8] showed moderate FOXM1
expression, whilst, the malignant HNSCC lines SqCC/Y1 [9]
and SCC25 [10] showed significant FOXM1 overexpression.
Furthermore, our bioinformatics analysis based on a panel of
microarray data [11] showed that FOXM1 mRNA expression was
significantly upregulated in both premalignant dysplastic lesions
(leukoplakia and erythroplakia) and HNSCC compared to normal
oral mucosa (Fig. 1B). In agreement, an independent real-time
quantitative RT-PCR (qPCR) study involving 15 patients’
HNSCC-derived primary cells showed significant ,5.1-fold
(P,0.001) upregulation of FOXM1 mRNA compared to normal
oral keratinocyte samples derived from four different patients
(Fig 1C). FOXM1 protein expression was next confirmed by
immunohistochemistry on a separate panel of human oral tissues
showing significant increase in FOXM1 protein expression in
moderate and severely dysplastic lesions, primary HNSCC and
lymph node metastasis (Fig. 1D–I). Digital densitometry of these
immunostained sections showed a trend of progressive increase in
FOXM1 protein levels from moderate dysplasia to lymph node
metastasis (Fig. 1J). All control normal oral mucosa (NOM) tissues
examined in this study showed low basal levels of FOXM1 mRNA
and protein levels. These results are in agreement with a separate
experiment using immunofluorescent staining to detect endoge-
nous FOXM1 protein levels on cultured primary normal human
oral keratinocyte (NHOK1), dysplastic (DOK) and HNSCC
(UK1) cells (Fig. 2A; Supplemental Fig. S1). Digital pixel
densitometry was used to quantify the levels of FOXM1 protein
expression (Fig. 2B). In NHOK1 cells, FOXM1 protein was
detected at low levels mainly within nuclei of dividing cells but not
expressed in non-dividing cells. In contrast, FOXM1 expression
was highly expressed in both dividing and non-dividing UK1 cells.
In DOK and UK1 cells, FOXM1 protein levels were significantly
upregulated by 2.4-fold (P,0.05) and 9.2-fold (P,0.001),
respectively, over NHOK1 cells (Fig. 2C). Western blotting
showed significant upregulation of endogenous FOXM1 protein
in both premalignant (POE9n, D20) and HNSCC (CaLH2,
CaDec12, UK1, 5PT) cell lines compared to normal oral
keratinocytes (NHOK1, NHOK355; Fig 2D). Almost all (n=6)
normal oral keratinocyte patient’s samples that we have tested
have shown equally low levels of FOXM1 protein (data not
shown). Growth factor or serum starvation in an oral premalignant
(POE9n) and HNSCC (UK1) cell line did not reduce the
endogenous mRNA of FOXM1B in these cells indicating that
upregulation of FOXM1 in these cells was not simply due to
increased cell proliferation (Fig. 2E). qPCR results showed that a
number of known FOXM1B target genes such as CENPF,
CENPA, NEK2 and cyclin B1 (CCNB1) were significantly
upregulated in UK1 cells compared to NHOK1 (Fig. 2F) showing
that FOXM1B in HNSCC cells was transcriptionally active. These
results showed for the first time that FOXM1 expression is
upregulated early in oral premalignant tissues and its expression
persists in both primary HNSCC and lymph node metastasis.
To further investigate FOXM1 expression in other human
tissue types, we performed bioinformatics analyses on published
microarray data on premalignant lesions including Barrett’s
metaplasia, uterine fibroid, atypical ductal hyperplasia that later
developed into cancer, all showed statistically significant FOXM1
upregulation (Fig. 3). Analyses of malignant cancer tissues showed
that FOXM1 was significantly upregulated in HNSCC (3.1-fold),
oesophagus adenocarcinoma (3-fold) and lung malignant meso-
thelioma (2.4-fold; see Fig. 3B). Taken together, these data confirm
that FOXM1 expression is upregulated early in a number of
premalignant tissues as well as malignant cancers. This supports a
key role for FOXM1 in early oncogenesis.
Nicotine activates FOXM1 transcriptional activity and
promotes FOXM1B-induced anchorage-independent
transformation of oral keratinocytes
Tobacco and betel quid are two known risk factors for the
development of HNSCC. In order to investigate the role of
FOXM1 in response to these oral risk factors, we tested our
hypothesis that nicotine (one of the major alkaloids found in
tobacco), arecoline and arecaidine (the main alkaloids found in
FOXM1 in Early Oncogenesis
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4849Figure 1. Upregulation of FOXM1 in both human oral premalignant and HNSCC tissues. (A) Semi-quantitative RT-PCR showing the
relative expression levels of total FOXM1 mRNA in normal oral mucosa (NOM; #1–2), moderate dysplasia (MD; #3–4), severe dysplasia (SD; #5–6),
primary HNSCC (#7–8), premalignant oral keratinocytes SVpgC2a, HNSCC cell lines SqCC/Y1 and SCC25. POLR2A was used as an endogenous
reference gene. (B) Bioinformatics analysis of microarray data performed on primary cells extracted from normal oral mucosa (NOM), leukoplakia,
erythroplakia and primary HNSCC with sample number as indicated. Statistically significant (***P,0.001) activation of FOXM1 mRNA levels when
compared to NOM. (C) Quantitative real-time RT-PCR showing relative fold change in FOXM1 mRNA expression levels in HNSCC-derived keratinocytes
(n=15) compared to normal oral mucosa keratinocytes (NOK; n=4). (D–I) Immunohistochemistry of FOXM1 protein on a panel of FFPE normal oral
mucosa (D), mild/moderate dysplasia (E), moderate/severe dysplasia (F), severe dysplasia/carcinoma in situ (G), primary HNSCC (H) and lymph node
HNSCC metastasis (I). (J) Digital pixel densitometry for FOXM1 protein immunoreactivity in a panel of 25 oral tissues (n=5 in each group) as shown in
D–I. **(P,0.01) and ***(P,0.001) indicate statistically significant elevation of FOXM1 protein levels when compared to NOM tissues.
doi:10.1371/journal.pone.0004849.g001
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transcriptional activity in cells. A FOXM1 luciferase reporter assay
was performed on a premalignant buccal keratinocyte line
SVpgC2a [8], a malignant human buccal squamous cell
carcinoma line SqCC/Y1 [9] and an tongue HNSCC line
SCC25 [10,12]. Nicotine, at physiologically relevant doses for
tobacco chewers, was found to induce a dose-dependent activation
of endogenous FOXM1 activity in all three cell types (Fig. 4A).
The effect of nicotine on FOXM1 activity was more potent on the
premalignant SVpgC2a cells (pEC50 4.43) than on the two
malignant lines SCC25 (pEC50 3.46) and SqCC/Y1 (pEC50 4.36).
In addition, nicotine was able to produce a higher level of
FOXM1 activity in SVpgC2a (.3-fold) cells compared to SqCC/
Y1 or SCC25 (,2-fold). This could be due to the higher
endogenous FOXM1 levels already present in SqCC/Y1 and
SCC25 (see Fig. 1A). Arecoline and arecaidine showed no effect
on FOXM1 transcriptional activity in either cell type (Fig. 4B–C).
None of these alkaloids at their respective highest doses affected
SCC25 cell viability (Fig. 4D–F). However, in the case of
SVpgC2a cells, the highest dose of nicotine (10
22 M), arecoline
(10
23 M) and arecaidine (10
23 M) showed significant decrease in
cell viability (Fig. 4D–F) indicating that the oral premalignant cell
line is generally more sensitive compared to the two HNSCC cell
lines. In line with the pattern of sensitivity, nicotine greater than
10
23 M (1 mM) were toxic to primary normal human oral
keratinocytes (data not shown). Endogenous mRNA levels of
FOXM1B were found to be dose-dependently elevated by nicotine
(Fig. 4G). Consistently, FOXM1 protein levels were also dose-
dependently increased by nicotine in both the premalignant
SVpgC2a cell line and in normal primary oral keratinocytes
(Fig. 4H). Furthermore, calf-intestinal alkaline phosphatase (CIP;
Fig. 4H lower panels) treatment in protein lysates from either
control DMSO or nicotine treated cells showed that FOXM1
protein becomes heavily phosphorylated after nicotine treatment,
which is a well established mechanism leading to FOXM1 protein
stabilisation and increased transactivation [13,14]. Using a
FOXM1 specific short-hairpin RNA interference plasmid
(shFOXM1) to knockdown endogenous FOXM1 gene expression,
nicotine-induced FOXM1 activity was significantly inhibited
confirming the direct effect of nicotine on FOXM1 activation.
The control shCTRL bearing a random sequence did not inhibit
nicotine-induced FOXM1 activity (Fig. 4I).
Given that SVpgC2a cells were more sensitive to nicotine-
induced cell death than SqCC/Y1 or SCC25 cells, we
hypothesized that upregulation of the cancer-associated FOXM1B
isoform in SVpgC2a may protect cells from nicotine toxicity
relevant to direct nicotine exposure in tobacco chewers. To test
this, we compared nicotine toxicity in SVpgC2a (bearing relatively
lower levels of endogenous FOXM1B; see Fig. 1A) with SqCC/Y1
and SCC25 (both bearing high endogenous FOXM1B levels; see
Fig. 1A). FOXM1B, overexpression in SVpgC2a but not the
empty vector significantly (P,0.001) protected cells from nicotine-
induced cell death (Supplemental Fig. S2). Whereas nicotine did
not induce cell death in SqCC/Y1 and SCC25 cells. We
subsequently hypothesized that upregulation of FOXM1B in
SVpgC2a may help these cells to gain survival advantage and may
promote anchorage-independent transformation following nico-
tine exposure. Indeed, we have found that upregulation of
FOXM1B induces anchorage-independent growth and malignant
transformation in SVpgC2a following nicotine exposure (Fig. 4I).
FOXM1B overexpression alone in SVpgC2a cells did not produce
any transformed clones in the soft-agar colony forming assay (data
not shown). Control EGFP-expressing SVpgC2a cells exposed to
nicotine did not produce transform colonies (Fig. 4J). Collectively,
our results showed that upregulation of FOXM1B protected cells
from nicotine-induced toxicity and promoted anchorage-indepen-
dent growth. Although many HNSCC lines do not grow well in
agar, some do and most grow better than normal keratinocytes
[12], suggesting that anchorage independence is a valid assay of
malignant transformation.
FOXM1B induces non-random genomic instability
With an aim to identify FOXM1B-target genes involved in
malignant transformation, we next questioned if the FOXM1B-
transformed clones we generated in Fig. 4H may harbour
‘signature’ genomic instability loci associated with malignant
transformation. Eight transformed clones (SVFN1-8) were isolated
from the soft-agar plates and grown into individual cell lines and
their genomic DNA extracted for genome-wide SNP array
profiling (Fig. 5A) to obtain genomic instability in the form of
loss of heterozygosity (LOH) and copy number abnormality
(CNA). LOH and CNA loci were identified by comparing SNP
genotype profiles between test cell samples with wild-type parental
SVpgC2a cells (non-transformed). Nicotine treatment alone did
not result in genomic instability in the wild-type parental
SVpgC2a cells (data not shown) or in the non-transformed
SVpgC2a cells expressing EGFP and treated with nicotine
(Fig. 5B–C). Non-transformed nicotine-treated FOXM1B express-
ing cells showed low levels of LOH and CNA (loss) in chromosome
13 (Supplemental Fig. S3). Whereas, all 8 transformed SVFN
clones showed significantly elevated LOH and CNA. All 8 SVFN
clones had significantly higher levels of FOXM1B mRNA (Fig. 5D)
indicating that these clones were derived from FOXM1B-
transduced parental cells. Using FOXM1 isoform-specific qPCR
(Supplemental Fig. S4), FOXM1A and FOXM1C mRNA were
not differentially expressed between the wild-type SVpgC2a and
SVFN cells (data not shown). In agreement with the mRNA levels
(Fig. 5D), western blotting showed increased FOXM1 protein
levels in all the 8 SVFN clones compared to wildtype SVpgC2a
cells confirming that FOXM1 expression is retained and that
upregulation of FOXM1B confers a selective advantage required
for anchorage-independent transformation (Fig. 5E). SNP analysis
on primary human oral keratinocytes showed that whilst
FOXM1B overexpression alone was not sufficient to induce
LOH, we observed significant (Fig. 5F) elevation of CNA
Figure 2. Intracellular expression of endogenous FOXM1 protein in primary cultures of human normal oral mucosa (NHOK1),
dysplasia (DOK) and HNSCC (UK1). (A) Fluorescence images showing intracellular localisation of FOXM1 (green) in respective cells
counterstained by a nuclear-stain DAPI (blue). The bottom panels are FOXM1 and DAPI merged images of high-power magnification (6400) showing
nuclear localisation of FOXM1 protein. (B) Histogram of FOXM1 protein expression levels in 50 cells analysed arranged from low to high FOXM1 levels.
(C) Mean FOXM1 protein expression levels in HNOK1, DOK and UK1 cells, n=50 cells analysed in (B). (D) Immunoblotting for endogenous FOXM1
protein in normal (NHOK1 and NHOK355), dysplasia (POE9n and D20) and HNSCC (CaLH2, CaDec12, UK1 and 5PT) cell lines as indicated. b-Tubulin
was immunoblotted for loading control in each sample. (E) Serum starvation (24 h) did not alter the endogenous FOXM1B mRNA levels in primary
NHOK1, premalignant POE9n or UK1 HNSCC cells. (F) qPCR data showed that known FOXM1B target genes such as CENPF, CENPA, NEK2 and cyclin B1
are upregulated in UK1 compared to NHOK1 cells. *(P,0.05), **(P,0.01) and ***(P,0.001) indicate significant increase in FOXM1 protein levels when
compared to NHOK1 cells.
doi:10.1371/journal.pone.0004849.g002
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higher frequency of CNA than LOH within the SVFN clones
(compare Fig. 5B and 5C).
FOXM1 target genes identification within recurrent LOH
loci
Comparison of genome-wide LOH profiles of the 8 SVFN
transformed clones revealed a non-random pattern of genomic
instability induced by FOXM1B and nicotine (Fig. 6A). The
chromosome 13 LOH retained in all the 8 SVFN transformed
clones confirms that the clones originated from FOXM1B
overexpressed cells. Apart from chromosome 13, the most
common recurrent LOH loci (.6 clones) detected in the 8 clones
were found in chromosome 4, 10 and 18 (Fig. 6B). Using a
selection criterion based on putative functional relevance to
oncogenesis, 9 candidate FOXM1B-induced transformation target
genes found within these common loci were short listed for further
investigation. We first screened gene expression levels using qPCR
comparing non-transformed SVpgC2a cells and the SVFN
transformed clones to identify putative FOXM1B-target genes.
Of the 9 shortlisted genes, CENTD1, CEP55 and HELLS, showed
a correlation between mRNA levels and their respective copy
number status (Fig. 7A). CENTD1 was found to be located within
a locus of uniparental disomy (UPD) with no change in copy
number and consistently qPCR data showed no change in
CENTD1 mRNA levels in the SVFN clones and as a result this
gene was not investigated further. Whereas, CEP55 and HELLS
located within a copy number gain loci showed significantly
elevated levels of mRNA in the SVFN clones. This suggests that
CEP55 and HELLS may be targets of FOXM1B for malignant
transformation.
CEP55 and HELLS are downstream targets of FOXM1
To investigate if FOXM1B may be driving the expression of
CEP55 or HELLS genes in oral keratinocytes, we transduced
primary human oral keratinocytes with retrovirus bearing either
MCS (empty viral vector), EGFP or FOXM1B and subsequently
mRNA was harvested from these cells for qPCR. Indeed, qPCR
data showed that upregulation of FOXM1B in primary oral
keratinocytes led to significant activation of CEP55 (4.43-fold) and
HELLS expression (4.21-fold; Fig. 7B). Consistent with the notion
that CEP55 is a target of FOXM1B, our bioinformatics analysis of
published microarray data (GEO Accession: GDS1477) in
FOXM1B-knockdown (by siRNA) breast cancer cells [15] showed
significant downregulation of CEP55 expression (Supplemental
Fig. S5). Similar bioinformatics analysis could not be performed
for HELLS because no data was available.
We next investigated the gene expression correlation of
FOXM1B with CEP55 and HELLS using qPCR in a panel of 8
normal human oral keratinocytes, 7 oral premalignant and 16
HNSCC cell lines (Fig 7C–H). As before, the endogenous levels of
FOXM1 protein in vivo (Fig. 1D–J), and in vitro (Fig. 2, Fig. S1) and
the endogenous FOXM1B mRNA in vitro, were significantly
upregulated in premalignant and HNSCC cells (Fig. 7C).
Endogenous mRNA levels of CEP55 (Fig. 7D) and HELLS
(Fig. 7E) were both significantly upregulated in oral premalignant
and HNSCC cell lines. Linear regression analyses showed that
mRNA expression profile of CEP55 (Fig. 7F; R
2=0.665)
correlated well with FOXM1B expression profile across the panel
of oral premalignant and HNSCC cell lines. HELLS mRNA
expression profile showed a weaker correlation with either
FOXM1B (Fig. 7G; R2=0.205) or CEP55 (Fig. 7H;
R
2=0.264). These results are in completely agreement with the
bioinformatics analysis of published microarray data (GEO
Accession: GDS1548; Supplemental Fig. S6) on a panel of 4
normal and 16 HNSCC patients’ tissues whereby FOXM1 (Fig.
S6A), CEP55 (Fig. S6B) and HELLS (Fig. S6C) are all upregulated
in HNSCC and that CEP55 (R
2=0.80; Fig. S6D) correlated
better than HELLS (R2=0.61; Fig. S6E) with FOXM1
expression.
CEP55 is a direct transcriptional target of FOXM1
We next investigated whether CEP55 and HELLS are direct
transcriptional targets of FOXM1 using chromatin immunopre-
cipitation qPCR (ChIP-qPCR) in normal human keratinocytes.
ChIP-qPCR results for the anti-FOXM1 (but not anti-GAPDH or
anti-cMYC) ChIP fraction showed that promoter copy number of
CEP55 were significantly higher in FOXM1B-transduced cells
compared to either mock or EGFP-expressing cells (Fig. 7I and
Supplemental Fig. S7A). However, promoter copy number of
HELLS was insignificant (Fig. 7J and Supplemental Fig. S7B) in
any of the IP fractions, suggesting that CEP55, but not HELLS, is
a direct target of FOXM1. Neither anti-GAPDH nor anti-cMYC
showed significant levels of either CEP55 or HELLS promoter
fragments indicating that the assay is specific. To further validate
these ChIP fractions, known FOXM1 transcriptional targets such
as cyclin B1 [16] (Supplemental Fig. S8A) and VEGF [17]
(Supplemental Fig. S8B–C) showed significantly higher copy
numbers of respective promoters in the anti-FOXM1 ChIP
fractions. FOXM1 did not bind to the promoter of the tumour
suppressor p16 (CDKN2A; Fig. S8D).
Discussion
The FOXM1 transcription factor is commonly overexpressed in
a variety of human malignancies and several studies have
suggested that this may be associated with malignant transforma-
tion [reviewed in 2,6]. Despite the fact that the FOXM1 gene
locus (12p13.3) has been reported to be amplified in HNSCC [18],
its mechanism of action in oral carcinogenesis has not yet been
investigated. This study provided the first evidence that FOXM1 is
upregulated in oral dysplasias and HNSCC samples collected from
various geographically distinct patient cohorts consisting of both
Caucasians and Asians (Fig. 1,2). Our bioinformatics analysis on
published microarray data on various other types of human
premalignant lesions and primary cancers confirmed that FOXM1
gene is commonly upregulated in a number of premalignant
tissues supporting its ubiquitous role in early oncogenesis.
Tobacco (both smoke and smokeless forms) and betel quid use
are the main risk factors for the development of HNSCC [19]. At
concentrations (0.01–10 mM) relevant to tobacco chewers,
nicotine, but not arecoline and arecaidine was found to activate
endogenous FOXM1 transcriptional activity through upregulation
of mRNA, protein levels and increased protein stabilisation
through phosphorylation in a dose-dependent fashion (Fig. 4).
The co-carcinogenic effect of nicotine supports the finding that the
risk of developing HNSCC is increased to 15 times higher in
Figure 3. Upregulation of FOXM1 in various human premalignant and primary cancers. (A) Bioinformatics analysis of published
microarray data on FOXM1 gene expression levels comparing various human tissue types of normal, premalignant and cancers. (B) Fold activation of
FOXM1 gene expression in individual tissue types over normal tissues as indicated.
doi:10.1371/journal.pone.0004849.g003
FOXM1 in Early Oncogenesis
PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4849FOXM1 in Early Oncogenesis
PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4849patients chewing betel quid with tobacco compared to chewing
betel quid alone [20]. Nicotine is currently perceived as a safe and
non-carcinogenic substance often used in tobacco replacement
therapy, despite increasing evidence that nicotine exhibit anti-
apoptotic effect in oral epithelial cells [21,22]. The growth
promoting effect of nicotine may explain the effect of nicotine
on FOXM1 activity. It has been shown that salivary nicotine
concentration can reach millimolar concentrations in tobacco
chewers. Nicotine chewing gum (eg. Nicorette, Nicotinell) contains
between 2–4 mg nicotine and is expected to produce millimolar
concentrations in the oral cavity. Some nicotine skin patches
contain up to 21 mg nicotine (NicoDerm) which can deliver up to
,3 mM/hr (500 ng.hr/ml) of plasma nicotine level [23] and is
expected to produce much higher nicotine concentration locally
on the skin. Although no evidence to date links nicotine exposure
alone to human cancer, it has been previously shown that nicotine
is co-carcinogenic with a tobacco smoke derivative benzo(a)pyrene
in causing skin cancer in mice [24]. A recently marketed nicotine-
supplemented drink (NICLiteH, Nichonica Ltd., California, USA)
contains 4 mg nicotine (2 cigarettes worth) and will produce up to
0.8 mM (125 ng/ml) plasma nicotine level within 6 hrs. We have
now shown that a concentration of nicotine as low as 0.1 mM was
able to elevate FOXM1 protein levels in primary human oral
keratinocytes (Fig. 4H). More alarmingly, nicotine-laced alcoholic
drinks (eg. Nicotini, a tobacco infused vodka or martini) are being
offered in bars and restaurants following smoking bans in various
developed countries. It has been reported that the synergistic
actions of severe alcohol and tobacco abuse can have over 100-fold
greater risk of developing HNSCC [25]. Our findings that nicotine
can directly activate the FOXM1 oncogene and the combined
action of FOXM1B upregulation and nicotine exposure may
induce malignant transformation (Fig. 8A) should prompt a
reassessment of the widespread use of nicotine-based tobacco
replacement therapies.
We believe that FOXM1B overexpression (1
st hit) alone in the
premalignant SVpgC2a cells may eventually induce transforma-
tion if cells were subjected to prolonged cell culture to allow
sufficient time to accumulate further oncogenic hits. We did not
see spontaneous FOXM1B-induced transformation during the
course of our study (6 months; data not shown). Hence, a semi-
toxic dose of nicotine (10 mM – a concentration relevant to
tobacco chewers) was used to expedite the selection of FOXM1B-
transformed SVpgC2a cells. Whilst nicotine at lower doses (0.1–
1 mM) activated FOXM1, nicotine at 10 mM did not activate
FOXM1 activity due to toxicity (Fig. 4A). This dose-related dual
effect of nicotine may explain its co-carcinogenic activity, ie, at low
doses it activates FOXM1B and at high doses it induces cell death
thereby enhancing oncogenic selection. Because FOXM1B
provides survival advantage, we believe that the fluctuating
nicotine exposure in long-term tobacco users serves as a selection
mechanism for oral cells with increased FOXM1B expression
thereby increasing the risk of malignant transformation through
subsequent genomic instability and accumulation of further
oncogenic hits.
We have shown for the first time using genome-wide SNP
profiling approach that acute upregulation of FOXM1B alone in
primary normal human oral keratinocytes was able to induce
random genomic instability in the form of CNA but not LOH
(Fig. 5F), indicating that FOXM1 overexpression alone is not
sufficient to induce LOH formation in normal cells. Nevertheless,
the upregulation of FOXM1B alone in a premalignant oral
keratinocyte line was able to induce LOH involving the whole of
chromosome 13. This is consistent with our previous finding that
chromosome 13 (13q14–q33) was a hotspot LOHin a premalignant
condition oral submucous fibrosis [26] and others have shown that
LOH in 13q21 is linked to the progression of HNSCC [27]. The
nicotine/FOXM1B-transformed malignant cell clones (SVFN1-8;
Fig. 5 & 6) exhibited multiple additional LOH/CNA loci. The non-
random pattern of LOH/CNA loci in these malignant clones
supports the phenomenon of field cancerisation often seen in
HNSCC [19,28] and numerous other cancers such as lung,
oesophagus, vulva, cervix, colon, breast, bladder and skin [29].
Although FOXM1B at physiological levels has been reported as
a regulator of DNA repair [30], its upregulation is likely to
interfere with the normal DNA repair mechanism leading to
enhanced genomic instability rather than enhanced DNA repair.
It is known that levels of many cell cycle-related genes are tightly
regulated and any deviations from their physiological critical
concentrations may cause problems. It has been shown that
silencing FOXM1 leads to genomic instability via aberrant
expression of mitotic spindle assembly genes such as CEPN-F,
Aurora B and Plk1, which are putative targets of FOXM1 [4]. We
have shown that overexpression of FOXM1B can also cause
genomic instability. In support, numerous studies have demon-
strated that proteins which are important in mitotic division are
often found amplified in human cancers giving rise to genomic
instability [31]. Whilst DNA repair and genomic instability may,
or may not, be directly inter-linked, FOXM1B induction may
trigger both DNA repair (aberrant repair) as well as genomic
instability. It is important to emphasise that our data (Fig. 1B)
showed that FOXM1 gene is significantly upregulated in
genomically unstable oral premalignant (dysplasia and erythro-
plakia) and HNSCC samples [11,32]. Moreover, upregulation of
FOXM1B in a wide variety of human cancers [6] is consistent
with our data that upregulation of FOXM1B causes genomic
instability. The findings that FOXM1B induces DNA repair genes
such as XRCC1 and BRCA2 [30] and the fact that most cancers
contain genomic instability [33] suggest that activation of DNA
repair and genomic instability may not be mutually exclusive in
cancer cells. Furthermore, the upregulation of FOXM1B in
Figure 4. Nicotine activated endogenous FOXM1 transcriptional activity and promoted FOXM1B-induced malignant transforma-
tion in human oral keratinocytes. (A–C) Dose-response curves of nicotine (A), arecoline (B) and arecaidine (C) on FOXM1 transcriptional activity in
SVpgC2a, SqCC/Y1 and SCC25 cells, respectively. (D–F) Cell viability assays on SVpgC2a, SqCC/Y1 and SCC25 cells treated with the indicated doses of
nicotine (D), arecoline (D) and arecaidine (F), respectively. Each data point indicates mean6SEM (n=3). ***(P,0.001) indicates significant cell death.
(G) qPCR shows that nicotine dose-dependently activated endogenous FOXM1B in SVpgC2a cells. (H) Immunoblotting shows that nicotine dose-
dependently activated endogenous FOXM1 protein in both the SVpgC2a (left panel) and primary normal human oral keratinocytes (right panel) as
indicated. Bottom panels showed that protein lysates were either pretreated with or without calf-intestinal phosphatase (CIP) prior to
immunoblotting. Nicotine at respective optimal doses for each cell type showed reduction of the phosphorylated FOXM1 (FOXM1-PP, top bands) in
CIP-treated lysates. b-Tubulin and b-catenin were used as loading control markers. (I) Reversal of nicotine-induced FOXM1 activation by RNA
interference shFOX. FOXM1 transcriptional activity was assayed in SVpgC2a cells co-transfected with either shCTRL (control shRNA; solid bars) or
FOXM1-specific shFOX (open bars) in either control (mock transfection), FOXM1-overexpressed or nicotine (1 mM)-treated cells, as indicated.
***(P,0.001) indicates significant repression of FOXM1 transcriptional activity over control cells. (J) Anchorage-independent cell transformation
assays of EGFP or FOXM1B-overexpressing and nicotine-treated (10 mM) SVpgC2a cells.
doi:10.1371/journal.pone.0004849.g004
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function is an important step in oncogenesis.
In search of FOXM1B-targeted malignancy associated genes,
micro-regions of consensus LOH loci shared amongst the 8
malignant clones were compared. The most common recurrent
LOH loci were found in 4p, 10q and 18q. Whilst this study did not
identify candidate genes within the 4p and 18q, these two loci have
been previously linked to HNSCC progression [34]. Our previous
study showed that LOH in 10q22–24 and 18q21 were hotspots in
oral premalignancy [26] and others have linked 10q with poor
HNSCC prognosis [35] and 18q with metastasis of HNSCC [36].
Within the amplified 10q23.33 LOH locus, we have identified a
centrosomal protein CEP55 (also known as URCC6, C10orf3 or
FLJ10540) and a stem cell marker/DNA helicase/chromatin
remodelling factor HELLS (also known as LSH, PASG,
SMARCA6, FLJ10339 or Nbla10143) [37] to be likely mediators
of FOXM1B-induced malignant transformation. CEP55 and
HELLS gene amplifications were found to be the commonest
among the transformed keratinocyte clones. In support, the
endogenous mRNA of both CEP55 and HELLS were significantly
activated by constitutive expression of FOXM1B in primary
human normal oral keratinocytes. Consistently, bioinformatics
analysis of published microarray data in FOXM1B-knockdown
(by siRNA) breast cancer cells [15] showed significantly decreased
levels of CEP55 (Supplemental Fig. S5). Our ChIP-qPCR results
suggest that FOXM1 protein binds directly to the promoter of
CEP55 (Fig. 7I) but not HELLS (Fig. 7J) indicating that CEP55 is
a direct transcriptional target of FOXM1, whilst HELLS may be
an indirect target. This finding may explain the lower correlation
between HELLS and FOXM1 expression (Fig. 7G and Supple-
mental Fig. S6E).
The upregulation of CEP55 and HELLS by FOXM1B in the
absence of nicotine suggests that nicotine acts as an upstream
enhancer of FOXM1B activity. Nicotine alone may not be
sufficient to achieve a critical FOXM1B threshold level required
for malignant transformation. Consistent with this notion, nicotine
alone failed to upregulate CEP55 or HELLS mRNA expression
(data not shown). This implies that nicotine exerts its co-
carcinogenic properties primarily through the enhancement of
FOXM1B rather than direct activation of CEP55 or HELLS.
Since FOXM1B alone can activate de novo expression of CEP55
and HELLS, we hypothesised that this de novo activation constitute
an initial oncogenic stress (1
st hit) which subsequently led to a
secondary genomic instability event resulting in a sustained CEP55
and HELLS expression through copy number amplification of
10q23 loci (2
nd hit). According to this model (Fig. 8B), at later
stages of malignancy, the expression of CEP55 and HELLS may
or may not be dependent on FOXM1B. In support for this model,
it has been shown previously [38] that upregulation of cyclin D1
(CCND1) expression was detected in oral hyperplasia/premalig-
nant lesions and CCND1 gene locus (11q13) amplification was
found in early dysplasia, carcinoma in situ and also metastatic
HNSCC. Furthermore, upregulation of CCND1 gene expression
was detected in premalignant lesions adjacent to HNSCC tumours
with amplified gene locus. In contrast no upregulation of CCND1
gene expression was detected in the premalignant lesions adjacent
to non-amplified tumours. Based on this model, we therefore
hypothesised that upregulation of CEP55 and HELLS precedes
gene amplification during malignant transformation induced by
FOXM1B.
Both CEP55 and HELLS mRNA levels were found to be
significantly elevated in both oral premalignant and HNSCC cell
lines compared to normal oral keratinocytes (Fig. 7D–E).
Consistent with their roles in malignancy, CEP55 is upregulated
in hepatocellular carcinoma and its overexpression induces
anchorage-independent growth, enhanced cell growth at low
serum levels and induction of tumourigenesis in nude mice [39].
FOXM1 is known to be overexpressed in hepatocellular
carcinoma [40]. A recent study involving 3 independent breast
cancer microarray datasets containing a total of 699 patients
revealed that CEP55 and FOXM1 are amongst the signature
prognostic markers which predicts breast cancer outcome [41].
HELLS has been implicated in leukaemia [42], non-small cell lung
cancer [43], breast cancer [44], and melanoma [45]. HELLS was
recently identified as one of the consensus genes expressed in
human embryonic stem cells [37]. The role of CEP55 in
midbody/cytokinesis [46,47] and HELLS in epigenetic DNA
methylation and chromatin maintenance [48] further support the
role of FOXM1B in genome maintenance [4]. We hypothesise
that aberrant upregulation of FOXM1B may be inducing genomic
instability through a program of malignant transformation
involving deregulation of cytokinesis (CEP55) and epigenetic
modifications (HELLS) whereby genomically unstable cells
acquire oncogenic survival advantage (Fig. 8B).
In summary, this study provides, for the first time, several lines
of evidence that FOXM1B is upregulated early during oral pre-
malignancy and its expression persists in primary and metastatic
HNSCC tissues. Cellular, molecular and genomic evidence have
shown that nicotine, at concentrations relevant to tobacco
chewers, significantly activated FOXM1 transcriptional activity
in oral keratinocytes. The synergistic action of nicotine and
FOXM1B overexpression led to anchorage-independent malig-
nant transformation of a premalignant oral keratinocyte line which
exhibited non-random genomic instability LOH/CNA profiles.
Analysis of consensus LOH loci identified CEP55 and HELLS
FOXM1B-target genes for malignant transformation. In conclu-
sion, the potential of FOXM1B, CEP55 and HELLS as early oral
cancer biomarkers deserves further investigation.
Materials and Methods
Samples
All clinical samples were collected according to local ethical
committee-approved protocols and informed patient consent was
obtained. Written informed consents and ethical approvals for all
clinical samples used in this study were obtained from each
institution where the samples were collected respectively. The
present study involved 4 independent cohorts of patients’ samples:
8 patients’ fresh frozen oral tissues (Fig. 1A), 23 patients’ primary
keratinocyte cultures’ microarray data [11] (Fig. 1B), 4 normal
primary oral mucosa keratinocytes and 15 HNSCC derived
primary cells were cultured as previously described [49] (Fig. 1C),
and 25 patients’ formalin-fixed paraffin embedded (FFPE) archival
tissues (Fig. 1D–J).
Figure 5. Upregulation of FOXM1B induces non-random genomic instability. (A) A schematic flow diagram showing the approach used in
this study to systematically ‘trace’ the genomic instability patterns (LOH and CNA) within the genomes of 8 individual nicotine/FOXM1B-transformed
clones using SNP microarrays. Levels of LOH (B), CNA (C), FOXM1B mRNA (using isoform-specific qPCR, see Supplemental Fig. S3) (D) and FOXM1
protein (E) in respective cell clones. (F) Levels of LOH and CNA in primary human normal oral keratinocytes expressing either EGFP or FOXM1B (n=3).
*(P,0.05), **(P,0.01) and ***(P,0.001) indicate significant increase over control cells.
doi:10.1371/journal.pone.0004849.g005
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PLoS ONE | www.plosone.org 11 March 2009 | Volume 4 | Issue 3 | e4849Figure 6. Identification of consensus LOH micro-loci in FOXM1B-transformed SVpgC2a cells. (A) Alignment of genome-wide LOH profiles
of non-transformed (FOXM1B) and FOXM1B-transformed SVpgC2a clones (SVFN1-8). Black lines indicate LOH at a given SNP loci. Histogram (red bars)
displays consensus regions of LOH across the 8 SVFN transformed clones. (B) Magnified and detail chromosomal view of the three consensus micro-
loci within chromosome 4, 10 and 18 with a list of genes located within each locus as indicated. Uniparental disomy (UPD, blue); copy number gain
(CN gain, red); copy number loss (CN loss, green); consensus LOH loci in at least 6 SVFN clones (pink).
doi:10.1371/journal.pone.0004849.g006
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Primary normal human oral keratinocytes (NHOK1-5, 16, 355,
376, 881) were cultured in a modified version of Keratinocyte
SFM (#17005-034 Gibco, Invitrogen) medium [50] containing
0.09 mM CaC12. K-SFM was supplemented with 25 mg/ml
bovine pituitary extract, 0.2 ng/ml EGF (#37000-015 Gibco,
Invitrogen), and 1% penicillin/streptomycin. Oral premalignant
cell lines: POE9n-hTERT/POE9n [50], DOK [51], D19, D20
and primary HNSCC derived cell lines: CA1, UK1, CaLH2,
CaLH3, CaDec11, CaDec12, H357, 5PT, PE3/JA, VB6, and
CaLH2-R [52] were kindly provided by Prof. Ian MacKenzie
(ICMS, Centre of Cutaneous Research, Barts and The London
School of Medicine & Dentistry). A non-transforming/premalig-
nant Simian virus 40T (SV40T) antigen immortalised human
buccal keratinocytes SVpgC2a [53] and a malignant human
buccal squamous cell carcinoma line SqCC/Y1 [9] were both
cultured in a low calcium (0.06 mM) EpiLifeH keratinocyte growth
medium (#M-EPI-500-CA; Cascade Biologics, TCS CellWorks
Ltd., Buckinghamshire, UK.) with growth factor supplements (#S-
001-5; Cascade Biologics). The malignant tongue-derived squa-
mous cell carcinoma keratinocytes, SCC25 [12] were maintained
in DMEM (Cambrex) supplemented with 10% FCS. Oral
dysplasia and primary HNSCC derived cell lines were grown
either in K-SFM, or RM
+ medium consisting of DMEM
supplemented with 25% Ham’s F12 medium (Gibco, Invitrogen),
10% FCS, 1% penicillin/streptomycin (Invitrogen, Paisley, UK),
and various mitogens (0.4 mg/ml hydrocortisone, 0.1 nM cholera
toxin, 5 mg/ml transferring, 20 pM lyothyronine, 0.18 mM
adenine, 5 mg/ml insulin and 10 ng/ml EGF). All cells were
grown at 37uC in a humidified atmosphere of 10% (for DMEM
and RM
+) or 5% (for K-SFM and EpiLife) CO2/95% air.
Bioinformatics analyses of microarray data
FOXM1 mRNA levels were analysed using published micro-
array data in various types of normal, premalignant and malignant
human tissues. These microarray datasets were obtained from the
Gene Expression Omnibus (GEO) database. Only studies that
compared normal with premalignant and/or malignant tissues
which used Affymetrix Gene Chip Human Genome U133A array
(GEO platform GPL-96) were selected for analysis. The
Affymetrix gene reference identification for FOXM1 was
202580_x_at. FOXM1 expression levels were statistically analysed
using Student’s t-test in Microsoft Excel software.
Real-time absolute quantitative RT-PCR
Poly-A
+ mRNA extraction, reverse transcription (RT) and real-
time absolute quantitative RT-PCR (absolute copy number
quantiation using standard curve for each gene) were performed
using SYBR green I Master (hot-start Taq polymerase master mix)
in the LightCycler 480 qPCR system (Roche Diagnostics Ltd,
England, UK). FOXM1 isoform specific primers were designed to
independently quantify each FOXM1 isoform. We have validated
that these primer pairs are highly specific for each isoform without
cross-amplification (see Supplemental Fig. S4). Common FOXM1
Figure 7. CEP55 and HELLS are putative FOXM1B target genes and are upregulated in both premalignant and HNSCC cell lines. (A)
mRNA levels of CEP55 and HELLS but not CENTD1 were significantly upregulated in SVFN transformed clones (solid bars) compared to non-
transformed SVpgC2a parental wild-type cells (open bars). (B) Exogenous overexpression of FOXM1B (determined using isoform-specific qPCR, see
Supplemental Fig S3), but not MCS (empty vector) or EGFP, in primary human normal oral keratinocytes (NHOK1) showed significant (***P,0.001)
induction of endogenous mRNA of CEP55 and HELLS, respectively. Fold mRNA expression levels of FOXM1B (C), CEP55 (D) and HELLS (E) in a panel of
oral premalignant cell lines (SVpgC2a, DOK, D19, D20, POE9n-hTERT, POE9n and OKT6) and HNSCC (CA1, UK1, CaLH2, CaLH3, CaDec11, CaDec12,
H357, 5PT, PE3/JA, VB6, CaLH2-R, BICR31, SCC4, SCC9, SCC15 and SqCC/Y1) compared to the mean6SEM (n=8) of normal primary human oral
mucosa cells (NHOK1-5, 16, 376, 881). Insets show mean6SEM fold mRNA expression levels of normal (n=8), oral premalignant (n=7) and HNSCC
cells (n=16). All three genes show statistically significant (*P,0.05; **P,0.01; ***P,0.001) upregulation in both oral premalignant and HNSCC cell
lines. (F) Linear regression analysis between FOXM1B and CEP55 expression in the panel of cell lines used in C and D. (G) Linear regression analysis
between FOXM1B and HELLS expression in the panel of cell lines used in C and E. (H) Linear regression analysis between CEP55 and HELLS expression
in the panel of cell lines used in D and E. Degree of correlation values (R
2) are given in each panel as indicated. (I–J) ChIP-qPCR assays for promoters of
CEP55 and HELLS in normal keratinocytes transduced with either Mock (empty virus), EGFP or FOXM1B. Antibodies for GAPDH and cMYC were used
as controls for immunoprecipitiation. Representative qPCR curves and melting peaks of each ChIP fractions could be found in Supplemental Fig. S7.
doi:10.1371/journal.pone.0004849.g007
Figure 8. A model mechanism of FOXM1-induced oncogenesis. (A) FOXM1 expression is upregulated early during the progression from
dysplasia to HNSCC malignancy. Nicotine may promote tumour development by synergising with the upregulation of FOXM1 during oncogenesis. (B)
Oncogenic 1
st hit represents overexpression of FOXM1 which directly activates CEP55 but indirectly activates HELLS expressions. This may destabilise
the genome through aberrant mitotic division/cytokinesis and/or epigenetic modification events induced by CEP55 and HELLS, respectively.
Oncogenic 2
nd hit represents the subsequent accumulation of further genomic instability (for example 10q23 amplification) which promotes
oncogenesis.
doi:10.1371/journal.pone.0004849.g008
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FOX-R 59-CGTGCAGGGAAAGGTTGT-39 were used to
detect all three FOXM1 isoforms. A panel of 8 human reference
genes (HPRT1, UBC, GAPDH, RPLP0, ESD, 18SRNA,
POLR2A and YAP1) [54,55] were initially tested on a panel of
human oral tissues used in this study (including normal gingival
mucosa, normal buccal mucosa, normal tongue, dysplasias and
HNSCC tissues), and keratinocyte cell types (including both
primary and cell lines). Using the GeNorm algorithm method [55]
and LightCycler 480 Relative Quantification Software (with built-
in multiple reference genes normalisation algorithm), of the 8
reference genes, we identified the two most reliable and stable
reference genes (POLR2A: POL-F, 59-GCAAATTCACCAAGA-
GAGACG-39; POL-R, 59- CACGTCGACAGGAACATCAG-39
and ESD: ESD-F, 59-TCAGTCTGCTTCAGAACATGG-39;
ESD-R, 59-CCTTTAATATTGCAGCCACGA-39) across the
aforementioned panel of human keratinocyte cells and tissues.
POLR2A and ESD were used as reference genes for all subsequent
qPCR experiments to calculate target gene expression levels.
Plasmid construction
The retroviral vector pSIN-IP-GFP (Self-Inactivating-Internal
Promoter-Green Fluorescence Protein [56] vector kindly provided
by Dr. Paul Khavari (Stanford University School of Medicine,
California,USA).TheconstructionofpEGFP-FOXM1B,retroviral
pSIN-EGFP-FOXM1B and the FOXM1-specific luciferase report-
er pGL3-5BS was described previously [5]. We have previously
validated that tagging of EGFP to the N-terminal of FOXM1B does
not alter the functional activity of FOXM1B isoform [5]. Both
EGFP and EGFP-FOXM1B transgenes are under the regulatory
control of a CMV promoter. In some experiments, the pSIN-MCS
(MCS) empty viral vector bearing no transgene was used as an
additional control. In all experiments, transduction of MCS or
EGFP did not produce any detectable biological artefacts. In this
manuscript, the terms FOXM1B and EGFP-FOXM1B are
synonymous and are used interchangeably to simplify descriptions.
Retroviral transduction, transfection and FOXM1-specific
transcriptional reporter assay
Retroviral supernatant was produced as previously described
[5]. Briefly, cells to be retrovirally transduced were plated at
10,40% confluence 24 hours prior to transduction. Cells were
pre-incubated for 5 minutes in growth medium containing 5 mg/
ml polybrene (hexadimethrine bromide; Sigma) before replacing
with retroviral supernatant containing the same concentration of
polybrene to facilitate infection. The cells in culture dishes with
viral supernatant was then centrifuged (3506g) at 32uC for 1 hour
before retroviral supernatant was replaced with normal growth
medium and kept in normal culture condition. For transient
transfection, cells were transfected using FuGENE 6 (Roche
Biochemicals) and FOXM1 luciferase reporter assays were
performed as described [5].
RNA interference
We used an H1 promoter-driven hairpin siRNA vector
(pSilencer 3.1-H1; Ambion Europe Ltd., Cambridgeshire, UK)
to express shRNA against FOXM1 using a previously validated
RNAi sequence [shFOX, CCTTTCCCTGCACGACATG [15]].
Keratinocytes were transfected with either shFOX or control
shCtrl (containing a random sequence CATAGATAGGACAT-
CAGCA which was validated to produce little off-target activity)
using FuGENE 6 (Roche) according to manufacturer’s protocol as
described previously [57].
Immunohistochemistry, fluorescence microscopy and
digital pixel densitometry
FOXM1 was immunostained with a rabbit polyclonal antibody
(K-19; Santa Cruz Biotechnology, California, USA) on paraffin
sections as described [58]. The reaction product was visualised
either with diaminobenzidine as a chromogenic substrate in FFPE
tissue sections or with Alexa Fluor 488 goat anti-rabbit IgG
secondary antibody (Molecular Probes, Invitrogen, Paisley, UK)
for fluorescence microscopy imaging in cultured cells. As described
previously [57,59], digital pixel densitometry was performed using
Adobe Photoshop CS3 (Adobe Systems Incorporated, USA)
utilising the Colour Range tool for colour-based quantification
or Lasso tool for manual selection of epithelial mucosa area and
subsequent pixel area readout from the Histogram data chart.
Whilst we have also used the ImageJ program for pixel
densitometry and obtained similar results, Photoshop was the
preferred choice for its accuracy, reproducibility and ease of use.
Western blotting
Cells were lysed in 16RIPA buffer [50 mM Tris 1 M, pH 7.3,
150 mM NaCl, 0.02% (w/v) SDS, 1% (v/v) Nonidet P-40,
100 mM sodium orthovanadate, 16 CM-EDTA complete mini
EDTA-free cocktail tablets (Roche Diagnostic)]. Cell lysates were
kept on ice for 20 min and centrifuged at 15000 rpm at 4uC for
20 min, and the supernatant was snap frozen in dry ice before
being stored at 280uC. Protein concentration was measured using
the Dc Protein Assay Kit (BioRad, Hertfordshire, UK). Proteins
were extracted in 56 SDS sample buffer (1 M Tris-HCL, 2 M
DTT, 1.5% Bromophenol Blue, 10% Glycerol, 20% SDS) and
briefly denatured for 5 min at 100uC before loading on SDS-
polyacrylamide gels. Proteins were then transferred to nitrocellu-
lose membranes (Hybond C-extra; Amersham). Membranes were
blocked in 5% non-fat dry milk in TBS (Tris buffered saline)
containing 0.1% Tween-20 (Sigma) (TBST) for 30 min at room
temperature. Next, membranes were probed with primary
antibodies in either 3% TBST milk or 5% BSA (bovine serum
albumin; Sigma) –TBST. Secondary antibodies were diluted in
3% TBST non fat dry milk. Antibodies used were rabbit
polyclonal anti-FOXM1 (C-20, Santa Cruz Biotechnology), anti-
b Tubulin (H235, Santa Cruz Biotechnology) and mouse
monoclonal anti-b Catenin (Sigma). Secondary antibodies used
were polyclonal rabbit anti-mouse immunoglobulin/HRP (Dako-
Cytomation, Cambridgeshire, UK), polyclonal goat anti-rabbit
immunoglobulin/HRP (DakoCytomation). Immunodetection was
performed with enhanced chemiluminescence reagent ECL+
(Amersham Pharmacia). For protein dephosphorylation, cell
lysates were incubated at 37uC for 1 hour in a mix containing
7.5 mg protein, 16Protease Inhibitor Cocktail (Roche), 16NEB
buffer 3 and 1 unit/mg protein of calf-intestinal alkaline
phosphatase (CIP; New England Biolabs). Sampels were then
denatured for 5 minutes at 100uC and were run on 6% SDS
PAGE and immunoblotted with the corresponding antibody.
Cell viability and anchorage-independent cell
transformation assay
CellTiter-Glo
TM luminescent assay (Promega, Madison, WI,
USA) was performed according to manufacturer’s instruction to
quantify ATP levels of metabolically active adherent cells.
Nicotine/FOXM1B-transformed SVpgC2a cells (10
5 cells) were
plated in growth medium on top of a layer of solidified 1% agarose
gel in tissue-culture plates. Culture medium was changed twice
weekly. During medium change, floating cells were collected by
centrifugation and re-introduced into the agarose dishes contain-
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FOXM1B-expressing cells survived the colony formation assay;
Fig. 4H) were individually aspirated using 200 ml pipette tips from
the agar dishes and subsequently propagated into individual
transformed clonal lines (SVFN1-8).
SNP microarray mapping assay
Genomic DNA (gDNA) samples were purified and processed as
described previously [60–62] with slight modification to the
standard GeneChip Mapping 10 K (V2.0) Xba Assay protocol
(Affymetrix Inc., Santa Clara, CA). Briefly, 350–500 ng of DNA
was digested with XbaI and ligated to the XbaI adaptor prior to
PCR amplification using AmpliTaq Gold with Buffer II (Applied
Biosystems, Foster City, CA). The PCR amplication profile on an
MJ DNA Engine thermal cycler was: 95/180 (hot start) and 95/
20, 59/15, 72/60 (uC/sec) for 40 cycles followed by a termination
step at 72uC for 7 mins. PCR products were purified using
Ultrafree-MC 30,000 NMWL filter columns (Cat#UFC-
3LTK00; Amicon) and DNA concentrations determined using
NanoDrop spectrophotometer. Hybridisation and scanning of the
arrays were processed as described previously [60–62]. LOH and
LOH likelihood were analyzed using Affymetrix Copy Number
Analysis Tool software (CNAT, version 4) where the threshold for
statistical significance was P#10-6 as recommended by Affymetrix
[63,64]. The data was cross verified and genome ploidy 6standard
deviation for Log 2 ratio values were obtained using an
independent algorithm, Copy Number Analyzer for GeneChip
(CNAG, version 2), which has been shown to improve signal-to-
noise ratios in heterogeneous genomes [65]. Average SNP call
rates for all chips were 95–99%. Putative genes within or adjacent
to the LOH SNPs were identified using IdeogramBrowser (version
0.20.0) [66] based on NCBI Human Genome Assembly (Built 36.2
database). Raw SNP data can be accessed from the NCBI’s GEO
database (GEO accession: GSE11782).
Chromatin immunoprecipitation qPCR (ChIP-qPCR)
ChIP was performed using the ChampionChIP
TM One-Day
Kit for qPCR (#1035A; SABiosciences Corporation, Frederick,
MD, USA) according to manufacturer’s protocol. To ensure that
the assay is properly controlled and specific, ChIP was performed
using anti-GAPDH, anti-cMYC or anti-FOXM1 antibodies each
on either mock, EGFP or FOXM1B-transduced keratinocytes.
Putative FOXM1 DNA binding sites [67] within promoter regions
(within 1 Kb upstream of gene) of CEP55 and HELLS were
identified using ClustalW2 sequence alignment tool [68]) and
qPCR primers flanking the putative binding site were designed
(Supplemental Fig. S9). Absolute qPCR was performed using the
LightCycler 480 qPCR system as described above.
Supporting Information
Figure S1 Upregulation of FOXM1 protein in oral premalig-
nant and HNSCC cell lines. Immunofluorescence imaging of
FOXM1 (FITC, green) and DNA (DAPI, blue) in normal
(NHOK1, HOK365), dysplasia (D20, POE9n) and HNSCC lines
(5PT, UK1).
Found at: doi:10.1371/journal.pone.0004849.s001 (3.37 MB TIF)
Figure S2 Upregulation of FOXM1B protected SVpgC2a cells
from nicotine-induced cell death. (A) Fluorescence microscopy
showing green fluorescence expression of EGPF or EGFP-
FOXM1B expressing SVpgC2a, SqCC/Y1 and SCC25 cells,
either treated with vehicle control (H20) or nicotine (10 mM) for
24 hours prior to experiment. Corresponding brightfield images
show respective cell density. (B) Digital densitometry quantification
of images in A showed that nicotine induced significant cell death
in EGFP-expressing SVpgC2a cells but not in FOXM1B-
expressing cells. Nicotine treatment did not show toxic effect on
SqCC/Y1 or SCC25 cells.
Found at: doi:10.1371/journal.pone.0004849.s002 (1.52 MB TIF)
Figure S3 FOXM1B overexpression alone in the premalignant
oral keratinocyte SVpgC2a cells induces LOH in chromosome 13.
Magnified view of LOH profiles in chromosome 13 across the 8
SVFN transformed clones with a list of randomly selected genes
found within the consensus LOH loci in this chromosome.
Found at: doi:10.1371/journal.pone.0004849.s003 (8.00 MB TIF)
Figure S4 FOXM1-isoform specific real-time quantitative RT-
PCR (qPCR). (A) A schematic diagram showing the relative
location of primers specific to each FOXM1 isoform. (B) Primer
sequences. (C) qPCR amplification curves demonstrating the
specificity of each isoform-specific primer pairs in the presence of
different FOXM1 isoform DNA templates (106 copies were added
in each qPCR reaction). These primer pairs only amplified specific
FOXM1 isoform and showed no cross-amplification in the
presence of inappropriate FOXM1 isoform templates. (D) Melting
analysis showed a single PCR product amplified by each pair of
primers respectively. (E) Agarose-gel electrophoresis confirmed the
correct PCR product size respective to each isoform. These PCR
products were subsequently validated by nucleotide sequencing
analysis (data not shown).
Found at: doi:10.1371/journal.pone.0004849.s004 (0.89 MB TIF)
Figure S5 Bioinformatics analysis of CEP55 gene expression
level from a published microarray dataset (GEO accession:
GDS1477) comparing BT-20 breast cancer cells expressing either
mock, siGFP or siFOX at 48 h post-transfection (Wonsey and
Follettie, 2005).
Found at: doi:10.1371/journal.pone.0004849.s005 (0.61 MB TIF)
Figure S6 Bioinformatics analysis of FOXM1, CEP55 and
HELLS gene expression level from a published microarray dataset
(GEO accession: GDS1548). Analysis of oral squamous cell
carcinoma (OSCC) cells from 16 patients and 4 healthy normal
oral tissue samples. OSCC cells were isolated from tumours by
laser capture microdissection. Results identify a strong correlation
between FOXM1 (A), CEP55 (B) and HELLS (C) gene expression
profiles and tumor invasiveness in OSCC. (D) Linear regression
analysis showed that CEP55 expression is highly correlated
(R2=0.8037) with FOXM1. (E) HELLS expression correlated
(R2=0.6132) less significantly with FOXM1. (F) CEP55 and
HELLS expressions showed poor correlation (R2=0.5289) with
each other.
Found at: doi:10.1371/journal.pone.0004849.s006 (1.02 MB TIF)
Figure S7 ChIP-qPCR for promoters of CEP55 and HELLS.
Representative qPCR fluorescence curves and melting analysis of
the promoters of CEP55 (A) and HELLS (B) on ChIP
(immunoprecipitate/IP; with either anti-GAPDH, anti-cMYC or
anti-FOXM1) and input (non-IP) fractions on mock, EGFP or
FOXM1B-transduced oral keratinocytes.
Found at: doi:10.1371/journal.pone.0004849.s007 (0.54 MB TIF)
Figure S8 ChIP-qPCR data for promoters of cyclinB1/CCNB1,
VEGF and p16/CDKN2A. Quantitative PCR data showing the
relative copy number of promoters of CCNB1 (A), VEGF (B–C,
promoter region 1 and 2) and CDKN2A (D) in the three ChIP
fractions (anti-GAPDH, anti-cMYC or anti-FOXM1) on mock,
EGFP or FOXM1B-transduced oral keratinocytes. *P,0.05,
**P,0.01 and ***P,0.001 indicate t-test significant levels.
Found at: doi:10.1371/journal.pone.0004849.s008 (0.24 MB TIF)
FOXM1 in Early Oncogenesis
PLoS ONE | www.plosone.org 16 March 2009 | Volume 4 | Issue 3 | e4849Figure S9 Primer sequences for ChIP-qPCR. qPCR primers
were designed within 1 kilobase upstream from +1 of each gene.
For CEP55 and HELLS promoters, primers were designed to
encompass putative FOXM1 binding site located using ClustalW2
sequence alignment tool (see Methods).
Found at: doi:10.1371/journal.pone.0004849.s009 (0.25 MB TIF)
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